http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
김권배,손의동,김중영,Kim, Kwon-Bae,Sohn, Uy-Dong,Kim, Choong-Young The Korean Society of Pharmacology 1992 대한약리학잡지 Vol.28 No.1
This study was designed to evaluate the responses of cardiovascular system to endothelin (ET) and neuropeptide Y (NPY) in 12 week-old SHR treated with or without enalapril (ENP) for 6 weeks. The diastolic blood pressure and heart rate were lower in ENP-treated SHR than in control. The pressor response to intravenous, but not intracerebroventricular, ET or NPY was attenuated by ENP treatment. The chronotropic action induced by electrical stimulation was attenuated by ENP or ET. The negative chronotropic action of ET was blocked by yohimbine. The increase in aortic tension induced by electrical field stimulation (EFS) was depressed in ENP-treated group as compared with non-treated group, and enhanced by ET, but not NPY, in the non-treated group. The ET-induced increase in tension was enhanced by removal of endothelium in the control group but not in ENP-treated group. The plasma concentration of norepinephrine and ET-induced increase in concentration of norepinephrine and epinephrine in plasma were decreased in ENP-treated group. These results suggest that preventive effect of enalapril on the development of hypertension may result from depressing vasoactive action of endothelin and neuropeptide Y, and sympathetic neurotransmission at peripheral nervous system. 선천성 고혈압 흰쥐(SHR)에서 endothelin-1(ET)과 neuropeptide Y(NPY) 투여에 의한 심혈관계 반응에 미치는 enallapril 장기처치의 영향을 검토하였다. 생후 6주의 SHR에 enalapril(3 mg/kg/day)을 6주간 투여하였을 때 고혈압 발현이 현저히 억제되었다(이하 enalapril 처치군). Enalapril 처치군에서 ET 및 NPY에 의한 승압반응이 현저히 억제되었지만, ET 측뇌실투여에 의한 혈압상승 및 NPY측뇌실 투여로 야기되는 혈압하강효과에는 영향이 없었다. 뇌척수제거 흰쥐에서 전기적 자극으로 야기되는 빈맥효과는 enalapril처치나 ET투여로 억제되었는데, ET의 작은 ${\alpha}_2$-수용체 길항제인 yohimbine 전처치로 봉쇄되었다. SHR의 적출 대동맥에서 전기자극 빈도수에 따르는 수축반응이 ET 전처치로 항진되었으나 NPY 전처치로는 차이가 없었다. 전기자극 빈도수에 따른 수축반응은 enalapril투여한 군의 것이 투여하지 않은 군의 것에 비하여 약화되었다. ET투여에 의한 혈중 norepinephrine의 증가작용이 enalapril처치로 감소되었으며, 이러한 감소작용이 뇌척수제거 흰쥐에서 현저하였다. 위의 결과로 미루어 고혈압흰쥐에 enalapril을 장기처치함으로써 고혈압 발현을 효과적으로 억제할 수 있으며, 이는 ET 및 NPY에 의한 승압반응 및 교감신경말단의 신경전달과정의 억제가 관여될 수도 있을 것 같다.
선천성 고혈압흰쥐에서 Endothelin과 Neuropeptide Y에 의한 심혈관계 반응에 Enalapril 장기처치가 미치는 영향
김권배(Kwon-Bae Kim),손의동(Uy-Dong Sohn),김중영(Choong Young Kim) 대한약리학회 1992 대한약리학잡지 Vol.28 No.1
선천성 고혈압 흰쥐(SHR)에서 endothelin-1(ET)과 neuropeptide Y(NPY) 투여에 의한 심혈관계 반응에 미치는 enallapril 장기처치의 영향을 검토하였다. 생후 6주의 SHR에 enalapril(3 mg/kg/day)을 6주간 투여하였을 때 고혈압 발현이 현저히 억제되었다(이하 enalapril 처치군). Enalapril 처치군에서 ET 및 NPY에 의한 승압반응이 현저히 억제되었지만, ET 측뇌실투여에 의한 혈압상승 및 NPY측뇌실 투여로 야기되는 혈압하강효과에는 영향이 없었다. 뇌척수제거 흰쥐에서 전기적 자극으로 야기되는 빈맥효과는 enalapril처치나 ET투여로 억제되었는데, ET의 작은 α<sub>2</sub>-수용체 길항제인 yohimbine 전처치로 봉쇄되었다. SHR의 적출 대동맥에서 전기자극 빈도수에 따르는 수축반응이 ET 전처치로 항진되었으나 NPY 전처치로는 차이가 없었다. 전기자극 빈도수에 따른 수축반응은 enalapril투여한 군의 것이 투여하지 않은 군의 것에 비하여 약화되었다. ET투여에 의한 혈중 norepinephrine의 증가작용이 enalapril처치로 감소되었으며, 이러한 감소작용이 뇌척수제거 흰쥐에서 현저하였다. 위의 결과로 미루어 고혈압흰쥐에 enalapril을 장기처치함으로써 고혈압 발현을 효과적으로 억제할 수 있으며, 이는 ET 및 NPY에 의한 승압반응 및 교감신경말단의 신경전달과정의 억제가 관여될 수도 있을 것 같다. This study was designed to evaluate the responses of cardiovascular system to endothelin (ET) and neuropeptide Y (NPY) in 12 week-old SHR treated with or without enalapril (ENP) for 6 weeks. The diastolic blood pressure and heart rate were lower in ENP-treated SHR than in control. The pressor response to intravenous, but not intracerebroventricular, ET or NPY was attenuated by ENP treatment. The chronotropic action induced by electrical stimulation was attenuated by ENP or ET. The negative chronotropic action of ET was blocked by yohimbine. The increase in aortic tension induced by electrical field stimulation (EFS) was depressed in ENP-treated group as compared with non-treated group, and enhanced by ET, but not NPY, in the non-treated group. The ET-induced increase in tension was enhanced by removal of endothelium in the control group but not in ENP-treated group. The plasma concentration of norepinephrine and ET-induced increase in concentration of norepinephrine and epinephrine in plasma were decreased in ENP-treated group. These results suggest that preventive effect of enalapril on the development of hypertension may result from depressing vasoactive action of endothelin and neuropeptide Y, and sympathetic neurotransmission at peripheral nervous system.
천병렬,김권배,김기식,김영조,김윤년,김창윤,박의현,신동구,심봉섭,이종주,이충원,장성국,전재은,Chun, Byung-Yeol,Kim, Kwon-Bae,Kim, Kee-Sik,Kim, Young-Jo,Kim, Yoon-Nyun,Kim, Chang-Yoon,Park, Wee-Hyun,Shin, Dong-Gu,Shim, Bong-Sub,Lee, Jong-Joo,L 대한예방의학회 1998 Journal of Preventive Medicine and Public Health Vol.31 No.3
To estimate the incidence rate of coronary heart disease in Korea, of all residents in Taegu city aged 25 or above, those who had an acute MI or a fatal coronary event between 1 July 1996 and 30 June 1997 were registered. Seven hundreds and eight patients were registered during the study period(685 were identified at hospital and 23 were autopsy cases). Age-standardized annual incidence rate of men in city area was 93 per 100,000(95% CI; 61-142) and 35% CI; 16-67) in women(100 in men and 20 in women aged 35-64). The incidence was rapidly increased after age 40 in men, however, in women after age 60. Twenty-eight-days case fatality rate was 45% in men and 47% in women. However, in the age group of 45-59 case fatality rate in women was two times higher than that in men. In conclusion, crude annual incidence rate of CHD in city area was 73 per 100,000 in men and 33 in women. The age-standardized annual incidence of CHD in men(93 per 100,000) was 2 times higher than that in women (33 per 100,000) in Korea.
한국인에서 심바스타틴의 효과와 부작용 분석을 위한 다기관 공동 임상 연구
박영배 ( Young-Bae Park ),서정돈 ( Jung-Don Seo ),배종화 ( Jong-Hwa Bae ),노영무 ( Young-Moo Rho ),이원로 ( Won-Ro Lee ),손민수 ( Min Soo Son ),채성철 ( Shung-Chull Chae ),김권삼 ( Kwon-Sam Kim ),김권배 ( Kwon Bae Kim ),안정천 ( J 대한내과학회 1999 대한내과학회지 Vol.57 No.5
The aim of this study was to investigate the efficacy of simvastatin to improved lipid profiles in hypercholesterolemic Korean patients. Methods : From 25 hospitals in Korea, 478 hypercholesterolemic patients were enrolled from November 1996 to April 1998. The inclusion criteria was hypercholesterolemia over 240 mg/dl after diet therapy for 1 month or hypercholesterolemia over 220 mg/dl in patients with definite evidence of ischemic heart disease. Simvastatin 10mg was started and doubled up to 40mg if total cholesterol level remained higher than 200 mg/dl at monthly check. Of 478 subjects, 344 patients in whom study protocol was not violated were analyzed. Results : Male to female ratio was 27:73 and 47% of the subjects were in 6th decade. Hypertension, coronary artery disease, and diabetes mellitus were present in 30, 10, and 4% of the subjects. Baseline lipid profile (mean of total cholesterol-LDL-HDL-triglyceride mg/dl) was 274-185-52-188. The dose of simvastatin for 3 months was 10/10/10mg in 61% of subjects, 10/20/20mg in 21%, 10/10/20mg in 7%, and 10/20/40mg in 12%. The change of total cholesterol level(before-4wk-8wk-12wk-withdrawal 4wk) was 274-209- 205-198-250, and the maximal reduction rate was 27%. The change of LDL-cholesterol was 185-123-116-110-159, with maximal reduction rate 39%. The change of HDL-cholesterol was 52-54-56-55-54, with maximal increase rate 9%. The change of tryglyceride was 188-161- 164-162-189, with maximal reduction rate 15%. The value before/after treatment of ApoA1, ApoB, and Lp(a) was 129/129, 138/83, and 9.3/10.7, respectively. The level of LDL-cholesterol at the end of treatment was below 100mg/dl in 36% of subjects, 100-130 in 45%, 130-160 in 16%, and over 160mg/dl in 4%. The reduction rate of LDL-cholesterol was different between subjects whose LDL decreased below 100 and those whose LDL did not decrease below 130mg/dl, which suggests the existence of the individual difference of responsiveness to simvastatin. There were only 3 subjects (0.9%) who showed increase of liver enzyme over 3 times as the upper normal limit. Conclusion: Simvastatin is effective in improving lipid profiles in hypercholesterolemic Korean patients without serious side effects. (Korean. J. Med 57:906-915, 1999)
ERCP 중 내시경으로 관찰된 39예의 십이지장 유두주변게실과 체담관 유두개구부가 게실내에 있는 4예에 대한 보고
김일환(Il Hwan Kim),김준택(Jun Taek Kim),문신길(Sin Kil Moon),김권배(Kwon Bae Kim),김약호(Tak Ho Kim),박승국(Seung Kook Park) 대한소화기학회 1983 대한소화기학회지 Vol.15 No.1
N/A The endoscopic observation and radiographic view during ERCP is considered to be the best method of recognizing the anatomical relationship between papilla of Vater and peri-Vaterian diverticulum. In the period of thirty three months by the end of 1982, 39 of 328 cases done ERCP were found to be peri-Vaterian diverticulum and the majority were older than forty of age with slight female predominance. Among the 39 cases of peri-Vaterian diverticulum, ten cases (25.6%) had calculi in biliary duct, four cases (10.2%) had acalculous cholangitis, two cases (5. 1%) had pancreatitis, ard 5 cases (12.8%) had nothing in bliary duct and pancreas but RUQ abdominal pain simillar to biliary colic, interestingly. Each of four patients whose bilio-pancreatic duct entering into diverticulum was found to have one of followings: bile duct stone with pancreatitis, cholangitis without stone, pancreatitis and colicky pain only.
신이철(Yi Chul Synn),김기식(Kee Sik Kim),배장호(Jang Ho Bae),한성욱(Seong Wook Han),박소영(So Young Park),남창욱(Chang Wook Nam),김기영(Ki Young Kim),김윤년(Yoon Nyun Kim),김권배(Kwon Bae Kim),김여희(You Hee Kim) 대한내과학회 2000 대한내과학회지 Vol.58 No.1
N/A Background : Exercise and pharmacologic stress echocardiography are widely used for detecting coronary artery disease. Arbutamine is a new synthetic mild α1-receptor and - receptor agonist developed specifically for stress echocardiography. Arbutamine is superior to dobutamine owing to its enforced chronotropic action than that of dobutamine. We intended to know safety and efficacy of arbutamine stress echocardiography in inducing myocardial ischemia and detecting coronary artery disease. Methods : We underwent arbutamine stress echocardiography on 52 patients, dobutamine stress echocardiography in 35 patients. Alteration of blood pressure, heart rate, regional wall motion on echocardiography were evaluated. Sensitivity and specificity were determined by coronary angiography for 61 patients(Arbutamine: 31, Dobutamine : 30) Results : 1) Hemodynamic alterations respect to stress agents Baseline Maximal Baseline Maximal Interval for Blood pressure Blood pressure Heartrate Heart rate maximal heartrate Arbutamine 122/70mmHg 138/72mmHg 69BPM 137BPM 8.2 min* Dobutamine 126/73mmHg 136/77mmHg 74BPM 102BPM 11.4 min* (* p < 0.05) 2) Comparison of Arbutamine and Dobutamine in sensitivity Sensitivity(Specificity) Side effects Atropine Arbutamine 80.1% (90%) 33(63.5%) 8(15.4%) Dobutamine 78.2% (71.4%) 21(60%) 7(20%) 3) Side effects of stress agents Hypotension Palpitation, tremor Arrhythmia Chest pain Arbutamine 15(28.8%)* 4(7.7%)* 21(40.4%) 8(9.2%) Dobutamine 3(8.6%)* 9(25.7%)* 12(34.3%) 5(5.7%) (* p < 0.05) 4) Premature ventricular contraction was most common arrhythmia in both group. There was no fatal or significant complication, and most complications were subsided after discontinuation of stress agents. Conclusion : Arbutamine is an effective and safe pharmacologic stress agent in detecting myocardial ischemia and superior to dobutamine in increasing heart rate. Sensitivity and specificity of arbutamine were higher than that of dobutamine.(Korean J Med 58:39-47, 2000)